Atypical antipsychotics in elderly patients with dementia;Atypiske antipsykotika hos eldre pasienter med demens

Tidsskrift for den Norske Laegeforening

Volumn 128, Issue 9, 2008, Pages 1060-1061

  Selbæk, Geir ^a,b   Engedal, Knut ^a,b,c  

^a Sykehuset Innlandet ^*

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; DEMENTIA; HUMAN; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RISK FACTOR; STROKE;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEMENTIA; HALOPERIDOL; HUMANS; METHOTRIMEPRAZINE; MIDDLE AGED; RISK FACTORS; RISPERIDONE; STROKE;

EID: 44949167757     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. www.emea.europa.eu/pdfs/human/press/pus/ 085604en.pdf (15.2.2008).
2. Ott A, Breteler MM, van Harskamp F et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995; 310: 970-3.
3. Steinberg M, Sheppard JM, Tschanz JT et al. The incidence of mental and behavioral disturbances in dementia: the cache county study. J Neuropsychiatry Clin Neurosci 2003; 15: 340-5.
4. Selbæk G, Kirkevold Ø, Engedal K. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry 2007; 22: 843-9.
5. Reseptregisteret. www.reseptregisteret.no/Prevalens.aspx (4.9.2007).
6. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167: 1269-70.
7. The Committee on Safety of Medicines. Atypical antipsychotic drugs and stroke. www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary= true&ssDocName=CON1004298&ssTargetNodeId=221 (25.11.2007).
8. Gill SS, Rochon PA, Herrmann N et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445.
9. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebocontrolled trials. JAMA 2005; 294: 1934-43.
10. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD003476.
11. Schneider LS, Dagerman KS, Insel P. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebocontrolled trials. Am J Geriatr Psychiatry 2006; 14: 191-210.
12. Schneider LS, Tariot PN, Dagerman K et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New Engl J Med 2006; 355: 1525-38.
13. Wang PS, Schneeweiss S, Avorn J et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 2335-41.
14. Fossey J, Ballard C, Juszczak E et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ 2006; 332: 756-61.